2SEVENTY BIO INC (TSVT)
US9013841070 - Common Stock
Taking everything into account, TSVT scores 4 out of 10 in our fundamental rating. TSVT was compared to 588 industry peers in the Biotechnology industry. The financial health of TSVT is average, but there are quite some concerns on its profitability. TSVT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TSVT had negative earnings in the past year.
In the past year TSVT has reported a negative cash flow from operations.
In the past 5 years TSVT always reported negative net income.
In the past 5 years TSVT always reported negative operating cash flow.
1.2 Ratios
TSVT has a better Return On Assets (-38.48%) than 62.16% of its industry peers.
TSVT has a Return On Equity (-85.22%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.48% | ||
| ROE | -85.22% | ||
| ROIC | N/A |
ROA(3y)-38.55%
ROA(5y)-51.18%
ROE(3y)-82.77%
ROE(5y)-228.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 83.16%, TSVT belongs to the best of the industry, outperforming 88.70% of the companies in the same industry.
TSVT's Gross Margin has declined in the last couple of years.
TSVT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.16% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.27%
GM growth 5Y-3.3%
2. Health
2.1 Basic Checks
TSVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
TSVT has more shares outstanding than it did 1 year ago.
TSVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -1.55, we must say that TSVT is in the distress zone and has some risk of bankruptcy.
TSVT has a Altman-Z score of -1.55. This is comparable to the rest of the industry: TSVT outperforms 52.91% of its industry peers.
TSVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.55 |
ROIC/WACCN/A
WACC9.34%
2.3 Liquidity
TSVT has a Current Ratio of 3.98. This indicates that TSVT is financially healthy and has no problem in meeting its short term obligations.
TSVT's Current ratio of 3.98 is in line compared to the rest of the industry. TSVT outperforms 44.52% of its industry peers.
TSVT has a Quick Ratio of 3.98. This indicates that TSVT is financially healthy and has no problem in meeting its short term obligations.
TSVT has a Quick ratio (3.98) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.98 | ||
| Quick Ratio | 3.98 |
3. Growth
3.1 Past
TSVT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.99%, which is quite impressive.
The Revenue has grown by 9.71% in the past year. This is quite good.
Measured over the past years, TSVT shows a quite strong growth in Revenue. The Revenue has been growing by 12.95% on average per year.
EPS 1Y (TTM)46.99%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-85%
Revenue 1Y (TTM)9.71%
Revenue growth 3Y-26.04%
Revenue growth 5Y12.95%
Revenue growth Q2Q-80.98%
3.2 Future
TSVT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.87% yearly.
TSVT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.24% yearly.
EPS Next Y52.61%
EPS Next 2Y35.28%
EPS Next 3Y24.26%
EPS Next 5Y14.87%
Revenue Next Year-21.45%
Revenue Next 2Y-1.48%
Revenue Next 3Y1.36%
Revenue Next 5Y11.24%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TSVT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSVT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TSVT's earnings are expected to grow with 24.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.28%
EPS Next 3Y24.26%
5. Dividend
5.1 Amount
No dividends for TSVT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2SEVENTY BIO INC
NASDAQ:TSVT (4/26/2024, 7:20:56 PM)
After market: 4.22 -0.04 (-0.82%)4.255
-0.04 (-0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap218.32M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.48% | ||
| ROE | -85.22% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.16% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.98 | ||
| Quick Ratio | 3.98 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)46.99%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y52.61%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)9.71%
Revenue growth 3Y-26.04%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y